Free Testosterone Level And Quality of Cauda Epididymis Sperm of Local Rabbit That Given Commercial Feed Supplemented By Cod Fish Liver Oil

2016 ◽  
Vol 2 (3) ◽  
pp. 1
Author(s):  
Ni Gusti Ayu Manik Ermayanti ◽  
I Gusti Lanang Oka ◽  
I Gede Mahardika ◽  
I Putu Suyadnya
Keyword(s):  
Testosterone Level ◽  
Sperm Quality ◽  
Free Testosterone ◽  
Fish Liver ◽  
Testosterone Levels ◽  
Commercial Feed ◽  
One Way Anova ◽  
Free Testosterone Level ◽  
Range Test

This study was intended to determine the free testosterone levels and sperm quality of local rabbit that was given commercial feed supplemented cod fish liver oil.  The experiment design that was used in this research was Complete Random Design (CRD) with four experiments of feed, i.e. commercial feed without cod fish liver oil (R-0) as control, commercial feed + 1,5% cod fish liver oil (R-1), commercial feed + cod fish liver oil 3% (R-2), commercial feed + cod fish liver oil 4,5% (R-3). The each experiment included eight rabbits and feed experiment was given starting by 13 weeks to 26 weeks years old. The variable that observed was free testosterone level and sperm quality of local rabbit. The data that was obtained to be analyzed with One Way Anova and if its contrast was done more test with Duncan’s Multiple Range Test (DMRT). The result of this research was to show that supplementation of cod fish liver oil in commercial feed was to show the result that a real distinction of (P<0, 05) towards free testosterone level and sperm quality of local rabbit.

scholarly journals Insulin Resistance, Hyperinsulinemia, and LH: Relative Roles in Peripubertal Obesity-Associated Hyperandrogenemia

2018 ◽  
Vol 103 (7) ◽  
pp. 2571-2582 ◽  
Author(s):  
Christine M Burt Solorzano ◽  
Karen L Knudsen ◽  
Amy D Anderson ◽  
Eleanor G Hutchens ◽  
Jessicah S Collins ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Insulin Sensitivity ◽  
Testosterone Level ◽  
Insulin Level ◽  
Tanner Stage ◽  
Free Testosterone ◽  
Sensitivity Index ◽  
Testosterone Levels ◽  
Steroidogenic Cell ◽  
Free Testosterone Level

Abstract Context Peripubertal obesity is associated with variable hyperandrogenemia, but precise mechanisms remain unclear. Objective To assess insulin resistance, hyperinsulinemia, and LH roles in peripubertal obesity–associated hyperandrogenemia. Design Cross-sectional analysis. Setting Academic clinical research unit. Participants Eleven obese (body mass index for age ≥95%) peripubertal girls. Intervention Blood samples were taken during a mixed-meal tolerance test (1900 to 2100), overnight (2100 to 0700), while fasting (0700 to 0900), and during an 80 mU/m2/min hyperinsulinemic-euglycemic clamp (0900 to 1100). Main Outcome Measures The dependent variable was morning free testosterone level; independent variables were insulin sensitivity index (ISI), estimated 24-hour insulin, and estimated 24-hour LH levels. Results All participants demonstrated insulin resistance and hyperinsulinemia. ISI, but not estimated 24-hour insulin level, correlated positively with morning free testosterone level when correcting for estimated 24-hour LH level and Tanner stage (rs = 0.68, P = 0.046). The correlation between estimated 24-hour LH and free testosterone levels approached significance after adjusting for estimated 24-hour insulin level and Tanner stage (rs = 0.63, P = 0.067). Estimated 24-hour insulin level did not correlate with free testosterone level after adjusting for estimated 24-hour LH level and Tanner stage (rs = 0.47, P = 0.20). Conclusion In insulin-resistant obese girls with hyperinsulinemia, free testosterone levels correlated positively with insulin sensitivity and, likely, circulating LH concentrations but not with circulating insulin levels. In the setting of relatively uniform hyperinsulinemia, variable steroidogenic-cell insulin sensitivity may correlate with metabolic insulin sensitivity and contribute to variable free testosterone concentrations.

Low Free Testosterone Level Predicts Frailty in Older Men. The Health in Men Study.

2010 ◽  
pp. OR17-3-OR17-3
Author(s):  
Z Hyde ◽  
L Flicker ◽  
OP Almeida ◽  
GJ Hankey ◽  
K McCaul ◽  
...  
Keyword(s):  
Testosterone Level ◽  
Free Testosterone ◽  
Older Men ◽  
Free Testosterone Level

P–050 The effectiveness of the platelet-rich plasma treatment of men with severe oligoasthenoteratozoospermia

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
O Somova ◽  
H Ivanova ◽  
N Sotnyk ◽  
K Kovalenko ◽  
I Feskova
Keyword(s):  
Male Infertility ◽  
Sperm Motility ◽  
Testosterone Level ◽  
Assisted Reproductive Technologies ◽  
Platelet Rich Plasma ◽  
Sperm Concentration ◽  
Free Testosterone ◽  
Reproductive Technologies ◽  
Positive Effects ◽  
Free Testosterone Level

Abstract Study question To evaluate the effect of platelet-rich plasma (PRP) testicular injections on spermogram parameters of men with severe oligoasthenoteratozoospermia (OAT). Summary answer The PRP testicular injections have beneficial effects on spermatogenesis and enhance sperm concentration and motility in infertile men with OAT. What is known already The use of PRP therapy in assisted reproductive technologies is debatable. Despite the recent evidence of its positive effects in promoting endometrial and follicular growth, data from clinical studies are limited. There are only a few papers on the effectiveness of PRP therapy in the treatment of male infertility and sexual dysfunction. In more detail, the influence of PRP on spermatogenesis was carried out only on experimental animals. Although the mechanisms of its action have not yet been clarified, it is assumed that PRP, containing many biologically active molecules, realizes its effect through the tissue regeneration and cell proliferation. Study design, size, duration This prospective study included 68 men (34.6±5.2) years old with severe OAT (≤4 million/ml, motility ≤30%, normal sperm morphology ≤1%) receiving hormonal and antioxidant (AO) therapy during 6 months before in vitro fertilization cycles. 33 of them were injected once with autologous PRP (0.5 ml in each testicle). Spermogram and testosterone level were analyzed before the treatment and in 3, 4 and 6 months after it. Participants/materials, setting, methods: Sperm concentration, motility and morphology in ejaculate of 33 men of PRP group were compared with those in the group of 35 men without PRP within 6 months of starting the treatment. Total and free testosterone level were measured in blood serum. PRP was prepared by centrifuging the patient’s own blood in the anticoagulant-containing tubes. The final concentration of platelets in the obtained sample was 950.000 – 1.250 000 cells in 1 ml. Main results and the role of chance 4 months after the PRP injection, sperm concentration and motility increased in 18 of 33 men of the PRP group compared with the baseline (before the treatment) – 4.2 (1.0; 6.9) vs 1.4 (0.1; 3.4) mln/ml (p &lt; 0.05) and 36.7 (30.6; 45.8) vs 17.7 (6.7; 28.2)% respectively (p &lt; 0.05).The maximum increase in sperm motility (but not in sperm concentration!) was observed in 24 men in 6 months – 49.6 (39.6; 56.4)% (p &lt; 0.05). Percent of morphologically normal spermatozoa in ejaculate slightly increased only in 12 men in that time period from 0–1% to 1–2%. The total testosterone level was 2.4 times higher than the baseline (31.6±7.2 vs 13.2±4.3 nmol/l, p &lt; 0.05), the free testosterone level was 1.8 times higher (14.5±3.5 vs 7.9±3.0 pgl/ml, p &lt; 0.05). Unlike the PRP group, in the group of men without PRP treatment, the sperm parameters did not changed compared with the baseline in 4 months after the starting hormonal and AO treatment. A significant increase of sperin concentration was observed only in 17 of 35 patients in 6 months. Sperm motility and percent of morphologically normal spermatozoa after the treatment did not differ from the baseline. Changes in the testosterone levels were similar to changes in PRP group. Limitations, reasons for caution Only young and middle-aged men were considered in the study. Large randomized controlled studies are required to confirm the PRP therapy efficacy and safety of f various fertility disorders. There are also no standardized protocols for PRP preparation. Wider implications of the findings: PRP therapy may have great potential for the treatment of male infertility and improving spermatogenesis. Optimization of methods of PRP preparation and dosage of testicular injections can enhance reproductive outcomes in assisted reproductive technologies. Trial registration number Not applicable

scholarly journals Late-Onset Hypogonadism in Latvia

2016 ◽  
Vol 9 (1) ◽  
pp. 164-164
Author(s):  
A. Pozarskis ◽  
◽  
J. Pozarska ◽  
J. Erenpreiss ◽  
◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Blood Serum ◽  
Testosterone Level ◽  
Rating Scale ◽  
Late Onset ◽  
Free Testosterone ◽  
Family Doctors ◽  
Late Onset Hypogonadism ◽  
Free Testosterone Level ◽  
Check Level

Objective: The aim of this study was to examine how common is LOH in Latvian men and to determine the target audience that needs screening for LOH. Design and Method: 300 men over the age of 40 who came to their family doctors and to sexologists were asked to complete the questionnaires for Aging Male Symptoms Rating Scale. Men were divided in three groups based on their age: 40-49 years old, 50-59 years old, and >59 years old. The men who according to the AMS questionnaires had suspicion of LOH symptoms were asked to check their level of testosterone in the blood serum. The authors also have summarized the data on the spread of different chronic diseases among the men. Results: 134 men were asked to check level of testosterone in the blood serum. 29% of men appeared to have hypogonadism. 38% of this men appeared to have adiposity, 77% - hypertension, 18% – diabetes, 51% – dislipidemia, 66%– erectile dysfunction. Among men with normal testosterone level adiposity was found in 29%, hypertension-in 56%, diabetes-in 5%, dislipidemia-in 39%, erectile dysfunction-in 61%. Significantly in hypogonadal men in the group 50-59 years was more frequent hypertension, and in all groups – diabetes mellitus. Conclusions: 1/3 of men aged 40 and older have diagnosis of LOH in the groups under research. It is necessary to check testosterone and free testosterone level: in all men 50-59 years old with arterial hypertension; in all men over the age of 40 with diabetes.

scholarly journals Effect of Eurycoma longifolia standardised aqueous root extract– Physta® on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study

2021 ◽  
Author(s):  
Sasikala M. Chinnappan ◽  
Annie George ◽  
Pragya Pandey ◽  
Govinda Narke ◽  
Yogendra Kumar Choudhary
Keyword(s):  
Quality Of Life ◽  
Free Testosterone ◽  
Total Testosterone ◽  
Double Blind ◽  
Testosterone Levels ◽  
Eurycoma Longifolia ◽  
Ageing Male ◽  
Secondary Endpoints ◽  
Male Subjects

Background: Low testosterone levels cause physiological changes that compromise the quality of life in ageing men. A standardised water extract from the root of Eurycoma longifolia (EL), known as Physta®, is known to increase testosterone levels. Objective: To evaluate the safety and efficacy of Physta® in improving the testosterone levels and quality of life in ageing male subjects. Design: This randomised, double-blind, placebo-controlled study enrolled 105 male subjects aged 50–70 years with a testosterone level <300 ng/dL, BMI ≥ 18 and ≤30.0 kg/m2. The subjects were given either Physta® 100 mg, 200 mg or placebo daily for 12 weeks. The primary endpoints were changes in serum total and free testosterone levels. The secondary endpoints included changes in the level of sex hormone-binding globulin (SHBG), dihydroepiandrosterone (DHEA), glycated haemoglobin (HbA1c), insulin-like growth factor-1 (IGF-1), thyroid function tests (T3, T4, TSH and Free T3) and cortisol. Changes in Ageing Male Symptoms (AMS) score, Fatigue Severity Scale (FSS) score and muscle strength are other secondary endpoints. The safety of the intervention products was measured by complete blood count, lipid profile, liver and renal function tests. Results: There was a significant increase in the total testosterone levels at week 12 (P < 0.05) in the Physta® 100 mg group and at weeks 4 (P < 0.05), 8 (P < 0.01) and 12 (P < 0.001) in the Physta® 200 mg group compared to placebo. No significant between-group differences in free testosterone levels were observed but a significant within-group increase occurred at weeks 4 (P < 0.01), 8 (P < 0.001) and 12 (P < 0.001) in the Physta®100 mg group and at weeks 2 (P < 0.01), 4 (P < 0.01), 8 (P < 0.001) and 12 (P < 0.001) in the Physta® 200 mg group. The AMS and FSS showed significant reduction (P < 0.001) in total scores at all time-points within- and between-group in both Physta® groups. DHEA levels significantly increased (P < 0.05) within-group in both Physta® groups from week 2 onwards. Cortisol levels significantly (P < 0.01) decreased in the Physta® 200 mg group, while muscle strength significantly (P < 0.001) increased in both Physta® groups at week 12 in the within-group comparison. There were no significant changes in SHBG. No safety related clinically relevant changes were observed. Conclusion: Supplementation of Physta® at 200 mg was able to increase the serum total testosterone, reduce fatigue and improve the quality of life in ageing men within 2 weeks’ time. Trial registration: This clinical study has been registered in ctri.nic.in (CTRI/2019/03/017959).

Abstract TP323: Does Serum Level Of Sex Hormones Before Rehabilitation Predict Functional Recovery In Elderly Post-stroke Patients?

Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Ryo Momosaki ◽  
Masahiro Abo ◽  
Wataru Kakuda
Keyword(s):  
Serum Level ◽  
Sex Hormones ◽  
Functional Recovery ◽  
Testosterone Level ◽  
Free Testosterone ◽  
Serum Levels ◽  
Stroke Patients ◽  
Post Stroke ◽  
Male Patients ◽  
Free Testosterone Level

Background: Sex hormone is recognized as a critical factor affecting physical function in the elderly. However, the influence of these hormones on functional recovery after stroke has not been studied in elderly patients. The objective of the study was to examine whether serum level of sex hormones before rehabilitation can predict clinical outcome in elderly post-stroke patients. Subjects and Methods: Seventy-on post-stroke hemiparetic patients who were hospitalized to our rehabilitation ward in their subacute-chronic phase, were subjected (age: 78 ± 6 years, period between onset and admission: 47 ± 31 days). On their admission, serum levels of dehydroepiandrosterone sulfate (DHEA-S) and free testosterone (only in male patients) were measured after an overnight fast. As functional measures, NIHSS and functional Independence Measure (FIM) were evaluated at their admission and discharge. We assessed the correlation between changes in serum levels of measured hormones and functional changes during hospitalization. Results: Neither DHEA-S nor free testosterone levels at admission correlated with the severity of stroke at admission. In male patients, significant positive correlation was found between free testosterone level at admission and FIM at discharge (r=0.31, p<0.05), although there was not significant correlation between DHEA-S level at admission and FIM change. Furthermore, the results of multivariate analysis showed that free testosterone level at admission significantly predicted the rate of FIM change during hospitalization in male patients. Conclusions: Serum level of free testosterone at the admission to rehabilitation ward can be a predictor of functional recovery in elderly male patients after stroke.

P-050 The effectiveness of the platelet-rich plasma treatment of men with severe oligoasthenoteratozoospermia

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
O Somova ◽  
H Ivanova ◽  
N Sotnyk ◽  
K Kovalenko ◽  
I Feskova
Keyword(s):  
Male Infertility ◽  
Sperm Motility ◽  
Testosterone Level ◽  
Assisted Reproductive Technologies ◽  
Platelet Rich Plasma ◽  
Sperm Concentration ◽  
Free Testosterone ◽  
Reproductive Technologies ◽  
Positive Effects ◽  
Free Testosterone Level

Abstract Study question To evaluate the effect of platelet-rich plasma (PRP) testicular injections on spermogram parameters of men with severe oligoasthenoteratozoospermia (OAT). Summary answer The PRP testicular injections have beneficial effects on spermatogenesis and enhance sperm concentration and motility in infertile men with OAT. What is known already The use of PRP therapy in assisted reproductive technologies is debatable. Despite the recent evidence of its positive effects in promoting endometrial and follicular growth, data from clinical studies are limited. There are only a few papers on the effectiveness of PRP therapy in the treatment of male infertility and sexual dysfunction. In more detail, the influence of PRP on spermatogenesis was carried out only on experimental animals. Although the mechanisms of its action have not yet been clarified, it is assumed that PRP, containing many biologically active molecules, realizes its effect through the tissue regeneration and cell proliferation. Study design, size, duration This prospective study included 68 men (34.6±5.2) years old with severe OAT (≤4 million/ml, motility ≤30%, normal sperm morphology ≤1%) receiving hormonal and antioxidant (AO) therapy during 6 months before in vitro fertilization cycles. 33 of them were injected once with autologous PRP (0.5 ml in each testicle). Spermogram and testosterone level were analyzed before the treatment and in 3, 4 and 6 months after it. Participants/materials, setting, methods Sperm concentration, motility and morphology in ejaculate of 33 men of PRP group were compared with those in the group of 35 men without PRP within 6 months of starting the treatment. Total and free testosterone level were measured in blood serum. PRP was prepared by centrifuging the patient’s own blood in the anticoagulant-containing tubes. The final concentration of platelets in the obtained sample was 950.000 – 1.250 000 cells in 1 ml. Main results and the role of chance 4 months after the PRP injection, sperm concentration and motility increased in 18 of 33 men of the PRP group compared with the baseline (before the treatment) – 4.2 (1.0;6.9) vs 1.4 (0.1;3.4) mln/ml (p &lt; 0.05) and 36.7 (30.6;45.8) vs 17.7 (6.7;28.2) % respectively (p &lt; 0.05).The maximum increase in sperm motility (but not in sperm concentration!) was observed in 24 men in 6 months – 49.6 (39.6;56.4) % (p &lt; 0.05). Percent of morphologically normal spermatozoa in ejaculate slightly increased only in 12 men in that time period from 0-1 % to 1-2%. The total testosterone level was 2.4 times higher than the baseline (31.6±7.2 vs 13.2±4.3 nmol/l, p &lt; 0.05), the free testosterone level was 1.8 times higher (14.5±3.5 vs 7.9±3.0 pgl/ml, p &lt; 0.05). Unlike the PRP group, in the group of men without PRP treatment, the sperm parameters did not changed compared with the baseline in 4 months after the starting hormonal and AO treatment. A significant increase of sperin concentration was observed only in 17 of 35 patients in 6 months. Sperm motility and percent of morphologically normal spermatozoa after the treatment did not differ from the baseline. Changes in the testosterone levels were similar to changes in PRP group. Limitations, reasons for caution Only young and middle-aged men were considered in the study. Large randomized controlled studies are required to confirm the PRP therapy efficacy and safety of f various fertility disorders. There are also no standardized protocols for PRP preparation. Wider implications of the findings PRP therapy may have great potential for the treatment of male infertility and improving spermatogenesis. Optimization of methods of PRP preparation and dosage of testicular injections can enhance reproductive outcomes in assisted reproductive technologies. Trial registration number not applicable

Sign in / Sign up

Export Citation Format

Share Document